RNAC Q2 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$298,000-99.1% YoY

Gross Profit

$298,000100.0% margin

Operating Income

-$22M-7319.1% margin

Net Income

$16M5330.9% margin

EPS (Diluted)

$0.60

QoQ Revenue Growth

-72.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$389M

Total Liabilities

$391M

Stockholders' Equity

-$3M

Cash & Equivalents

$160M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$298,000	$33M	-99.1%
Gross Profit	$298,000	$33M	-99.1%
Operating Income	-$22M	$14M	-258.5%
Net Income	$16M	$14M	+14.8%

Revenue Segments

Operating Segment

$298,000100%